MUR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Murphy Oil Corp (MUR) is not a strong buy for a beginner investor with a long-term strategy at this time. The technical indicators, options data, and financial performance do not present a compelling case for immediate investment. The stock's recent financial performance shows significant declines in revenue, net income, and EPS, while technical indicators suggest a neutral to slightly bearish trend. Analysts' ratings are mixed, with no strong consensus for upside potential. Given the lack of strong positive catalysts and the absence of Intellectia Proprietary Trading Signals, it is advisable to hold off on investing in MUR for now.
The MACD histogram is negative (-0.489) and contracting, indicating a lack of bullish momentum. The RSI is neutral at 51.018, and moving averages are converging, suggesting indecision in the market. Key support and resistance levels are at S1: 37.572 and R1: 42.377, with the current pre-market price at 38.80, close to support levels. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Some analysts have raised price targets, citing increased oil price forecasts and geopolitical factors such as the Iran conflict. Johnson Rice upgraded the stock to Accumulate with a $63 price target, which is significantly higher than the current price.
The company's financial performance in Q4 2025 showed significant declines in revenue (-8.44% YoY), net income (-76.38% YoY), and EPS (-76.47% YoY). Gross margin also dropped slightly. Additionally, the stock trend analysis indicates a 70% chance of a slight decline (-0.67%) in the next day and a minimal increase (0.22%) in the next week, suggesting limited short-term upside.
In Q4 2025, Murphy Oil's revenue dropped to $613.08M (-8.44% YoY), net income fell to $11.89M (-76.38% YoY), and EPS declined to $0.08 (-76.47% YoY). Gross margin decreased slightly to 34.58 (-1.03% YoY), indicating weakening profitability.
Analyst ratings are mixed. UBS and JPMorgan raised price targets to $44 but maintained Neutral ratings. Morgan Stanley raised its target to $37 but kept an Underweight rating. Johnson Rice upgraded the stock to Accumulate with a $63 price target, while Piper Sandler upgraded it to Overweight with a $41 target. Overall, there is no strong consensus for a bullish outlook.
